- Home
- TGHL vs NXL Comparison
TGHL vs NXL Comparison
Compare TGHL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | NXL |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | Singapore | United States |
| Employees | 7 | 8 |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TGHL | NXL |
|---|---|---|
| Price | $0.34 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.9K | ★ 714.0K |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.31 |
| 52 Week High | $3.80 | $2.00 |
Technical Indicators
Market Signals| Indicator | TGHL | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 77.32 |
| Support Level | $0.33 | $0.35 |
| Resistance Level | $0.40 | $0.62 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 43.67 | 93.84 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.